Learning Hub Central
Lung
2025 SPS Seattle | Taletrectinib Pushing Boundaries in ROS1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lung
Non-CME Credit Course
%20(dragged)-1759605261217.webp&w=3840&q=75)
2025 SPS Seattle | Supportive Care for Small Cell Lung Cancer (SCLC)
Lung
Non-CME Credit Course
-1759525827965.webp&w=3840&q=75)
2025 MLS Washington DC | ADCs Mechanism, Resistance and Future Perspectives
Lung
Non-CME Credit Course
-1759525717594.webp&w=3840&q=75)
2025 MLS Washington DC | Subsequent Therapies and BiTes in SCLC
Lung
Non-CME Credit Course
-1759525607075.webp&w=3840&q=75)
2025 MLS Washington DC | Improving Therapeutic Approaches to Frontline Therapy in Small Cell Lung Cancer
Lung
Non-CME Credit Course
-1759525468565.webp&w=3840&q=75)
2025 MLS Washington DC | Chasing Solutions: Innovative Approaches to Non-Targetable NSCLC
Lung
Non-CME Credit Course
-1759524075570.webp&w=3840&q=75)
2025 MLS Washington DC | RET, MET, BRAF NSCLC
Lung
Non-CME Credit Course
-1759523964787.webp&w=3840&q=75)
2025 MLS Washington DC | Strategies for KRAS Mutant NSCLC
Lung
Non-CME Credit Course
-%20Evolving%20Options%20(dragged)-1759523866045.webp&w=3840&q=75)
2025 MLS Washington DC | Exon 20 (HER2 ad EGFR): Evolving Options
Lung
Non-CME Credit Course
-1759523751108.webp&w=3840&q=75)
2025 MLS Washington DC | EGFR TKI Plus EGFR/Met Bispecific Antibody
Lung
Non-CME Credit Course
2025 MLS Washington DC | 3rd Generation EGFR TKI +/- Platinum Chemotherapy
Lung
Non-CME Credit Course
-1759523438568.webp&w=3840&q=75)
2025 MLS Washington DC | Treating Unresectable Stage III NSCLC
Lung
Non-CME Credit Course
-1759523305827.webp&w=3840&q=75)
2025 MLS Washington DC | Neoadjuvant Therapies for NSCLC
Lung
Non-CME Credit Course
-1759523214423.webp&w=3840&q=75)
2025 MLS Washington DC | Adjuvant Therapies for Resected NSCLC
Lung
Non-CME Credit Course
-1759523107062.webp&w=3840&q=75)
2025 MLS Washington DC | SBRT for Early-Stage NSCLC: Future Perspectives
Lung
Non-CME Credit Course
-1759522734313.webp&w=3840&q=75)
2025 MLS Washington DC | Minimal Residual Disease in Lung Cancer
Lung
Non-CME Credit Course
-1759522262573.webp&w=3840&q=75)
2025 MLS Washington DC | Lung Cancer Screening
Lung
Non-CME Credit Course
-1759522123024.webp&w=3840&q=75)
2025 MLS Washington DC | Precision Oncology in all Stages of NSCLC
Lung
Non-CME Credit Course
-1755990775594.webp&w=3840&q=75)
2025 CCC | Early Stage and Locally Advanced NSCLC
Lung
Non-CME Credit Course
-1755990554729.webp&w=3840&q=75)
2025 CCC | Updates in NSCLC Targeted Therapy
Lung
Non-CME Credit Course
-1755990700517.webp&w=3840&q=75)
2025 CCC | Advances in Small Cell Lung Cancer, Mesothelioma and Thymic Malignancies
Lung
Non-CME Credit Course
-1755988911432.webp&w=3840&q=75)
2025 CCC | Immunotherapy and Bispecifics in Lung Cancer
Lung
Non-CME Credit Course
-1753361183599.webp&w=3840&q=75)
2025 NOSCM | Where Are We in Treating Lung Cancer Driven by KRAS and HER2?
Lung
Non-CME Credit Course
-1753361094794.webp&w=3840&q=75)
2025 NOSCM | Updates on ROS-1, RET, BRAF, MET & NTRK
Lung
Non-CME Credit Course
-1753361001450.webp&w=3840&q=75)
2025 NOSCM | What is New in EGFR and ALK NSCLC?
Lung
Non-CME Credit Course
-1753360911472.webp&w=3840&q=75)
2025 NOSCM | Management of Unresectable Stage III NSCLC
Lung
Non-CME Credit Course
-1753360817149.webp&w=3840&q=75)
2025 NOSCM | Future Directions in the Management of Small Cell Lung Cancer
Lung
Non-CME Credit Course
-1753360687585.webp&w=3840&q=75)
2025 NOSCM | When and How to Apply Radiation Therapy in Oligometastatic, Oligopersister or Oligoprogression Disease?
Lung
Non-CME Credit Course
-1753360474536.webp&w=3840&q=75)
2025 NOSCM | The Perioperative Concept on Lung Cancer Treatment with the Advent of Immunotherapy
Lung
Non-CME Credit Course
-1753360248087.webp&w=3840&q=75)
2025 NOSCM | Innovative Biomarkers and Potential New Pathways in Lung Cancer
Lung
Non-CME Credit Course
2025 NOSCM | Lung Cancer Prevention in a World of Pollution: Will Particulates Change our Practice?
Lung
Non-CME Credit Course
-1750785214433.webp&w=3840&q=75)
2025 MLS Nashville | Immunotherapy Updates in Lung Cancer 2025
Lung
Non-CME Credit Course
-1750780084008.webp&w=3840&q=75)
2025 MLS Nashville | Target Therapy Updates in Lung Cancer 2025
Lung
Non-CME Credit Course
2025 MCM | Updates on SCLC and Mesothelioma
Lung
Non-CME Credit Course
2025 MCM | ADC in NSCLC: Too Much Hope?
Lung
Non-CME Credit Course
2025 MCM | Updated Management on Advanced NSCLC Driver Mutant Tumors
Lung
Non-CME Credit Course
2025 MCM | Stage III Unresectable NSCLC: Any Progress Beyond PACIFIC?
Lung
Non-CME Credit Course
2025 MCM | Utilization of Immunotherapy in the Perioperative Setting
Lung
Non-CME Credit Course
Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?
Lung
Non-CME Credit Course
2025 MCM | Updates on SCLC and Mesothelioma
Lung
Non-CME Credit Course
2025 MCM | ADC in NSCLC: Too Much Hope?
Lung
Non-CME Credit Course
2025 MCM | Updated Management on Advanced NSCLC Driver Mutant Tumors
Lung
Non-CME Credit Course
2025 MCM | Stage III Unresectable NSCLC: Any Progress Beyond PACIFIC?
Lung
Non-CME Credit Course
2025 MCM | Utilization of Immunotherapy in the Perioperative Setting
Lung
Non-CME Credit Course
2024 MLS Irvine | Target Therapy Updates
Lung
Non-CME Credit Course
2024 MLS Irvine | Immunotherapy Updates in Lung Cancer
Lung
Non-CME Credit Course
2024 NOSCM | Small Cell Lung Cancer: Targeting This Difficult Target
Lung
Non-CME Credit Course
2024 NOSCM | Non Driver NSCLC: The Immunotherapy Strategy
Lung
Non-CME Credit Course
2024 NOSCM | Other Driver Mutations: ROS-1, BRAF, MET and RET
Lung
Non-CME Credit Course
2024 NOSCM | K-RAS Therapies in NSCLC
Lung
Non-CME Credit Course
2024 NOSCM | ALK: First Line and Mechanism Of Resistance
Lung
Non-CME Credit Course
2024 NOSCM | EGFR Exon 20 Insertions: Novel Agents
Lung
Non-CME Credit Course
2024 NOSCM | What Is Next After Osimertinib Progression?
Lung
Non-CME Credit Course
2024 NOSCM | Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
Lung
Non-CME Credit Course
2024 NOSCM | Optimal Surgical Approach in Early Stages NSCLC
Lung
Non-CME Credit Course
2024 NOSCM | Screening in Lung Cancer: Challenges and Obstacles
Lung
Non-CME Credit Course
2024 NOSCM | Challenges in Lung Cancer Pathology: Biomarkers
Lung
Non-CME Credit Course
ctDNA in Lung Cancer: Current State and Future Perspectives
Lung
Non-CME Credit Course
2022 Best of WCLC | Other Oncogene-Driven Cancers
Lung
Non-CME Credit Course
PD-1 Inhibitor Update
Lung
Non-CME Credit Course
2024 NOSCM | Adjuvant Therapies in NSCLC
Lung
Non-CME Credit Course
2024 MLS Nashville | Target Therapy Updates in Lung Cancer 2024
Lung
Non-CME Credit Course
Immunotherapy Updates in Lung Cancer 2024
Lung
Non-CME Credit Course
2024 MCM | Bi-Specific Inhibitor & ADC in Lung Cancer
Lung
Non-CME Credit Course
2024 MCM | Immunotherapy in NSCLC: First Line for Advanced Disease
Lung
Non-CME Credit Course
2024 MCM | Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors
Lung
Non-CME Credit Course
2024 MCM | Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC
Lung
Non-CME Credit Course
2024 MLS Cleveland | Targeted Therapy Updates in NSCLC
Lung
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on Antibody Drug Conjugates & Bispecific Antibodies in NSCLC
Lung
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on Immunotherapy in NSCLC: Metastatic Setting and What is After First Line IO Failure
Lung
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on Targeting NSCLC Driver Pathways
Lung
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on Small Cell: The Updates
Lung
Non-CME Credit Course
Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 2)
Lung
Non-CME Credit Course
Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 1)
Lung
Non-CME Credit Course
2024 WCS | Efforts to Overcome Resistance to First Line Immunotherapy
Lung
Non-CME Credit Course
2024 WCS | Immunotherapy in Metastatic NSCLC: How to Choose Initial Therapy and What’s New?
Lung
Non-CME Credit Course
2024 WCS | Antibody Drug Conjugates in NSCLC
Lung
Non-CME Credit Course
2024 WCS | KRAS and EGFR Exon 20 Insertion
Lung
Non-CME Credit Course
2024 WCS | MET, RAF and NTRK
Lung
Non-CME Credit Course
2024 WCS | ALK, ROS-1 and RET
Lung
Non-CME Credit Course
EGFR and Resistant Mechanisms
Lung
Non-CME Credit Course
2024 PRIMO | Neoadjuvant and Adjuvant Immunotherapy
Lung
Non-CME Credit Course
2024 PRIMO | What’s New in EGFR, ALK, RET and c-MET
Lung
Non-CME Credit Course
2024 PRIMO | New Agents after Immunotherapy Resistance
Lung
Non-CME Credit Course
2023 UCT | New Developments in EGFR and K-RAS Therapies in NSCLC
Lung
Non-CME Credit Course
2023 UCT | Updates on Targeting ALK, ROS1 ,and RET in NSCLC
Lung
Non-CME Credit Course
2022 UCT | Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC
Lung
Non-CME Credit Course
2023 UCT | The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET
Lung
Non-CME Credit Course
Updates in Bispecific Antibodies in NSCLC
Lung
Non-CME Credit Course
TROP-2 and AXL as Targets in NSCLC
Lung
Non-CME Credit Course
Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)
Lung
Non-CME Credit Course
PARP Inhibitors in SCLC
Lung
Non-CME Credit Course
Optimal Management of Limited Stage SCLC
Lung
Non-CME Credit Course
Optimal Management of Extensive SCLC (1st and 2nd Line)
Lung
Non-CME Credit Course
NRG1 as Target in NSCLC?
Lung
Non-CME Credit Course
Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection
Lung
Non-CME Credit Course
KRAS mutant NSCLC: What is the Standard of Care Now?
Lung
Non-CME Credit Course
HER-3 as a New Target in NSCLC
Lung
Non-CME Credit Course
Developing New Anti-CTL4s for NSCLC: Is There Any Role?
Lung
Non-CME Credit Course
Building the Case for HER-2 Inhibitors in NSCLC
Lung
Non-CME Credit Course
Best Surgical Approaches for Stage III NSCLC
Lung
Non-CME Credit Course
2024 SPECTRUM | Robotic assisted Lung ablations
Lung
Non-CME Credit Course
2024 SPECTRUM | PEF in Lung Cancer
Lung
Non-CME Credit Course
2024 SPECTRUM | Approach to lung cancer in the UK
Lung
Non-CME Credit Course
2024 SPECTRUM | Optimizing radiation in primary lung malignancies
Lung
Non-CME Credit Course
2024 SPECTRUM | Advances in chemotherapy in Lung cancer
Lung
Non-CME Credit Course
2023 MLS Denver | Later lines of Treatment for NSCLC
Lung
Non-CME Credit Course
2023 MLS Denver | Immunotherapy Toxicities and Lung Biomarkers
Lung
Non-CME Credit Course
2022 MLS Denver | Lung Immunotherapy
Lung
Non-CME Credit Course
2022 MLS Denver | Targeted Therapies in Lung Cancer
Lung
Non-CME Credit Course
2022 MLS Denver | Early-Stage/Locally Advanced Lung Cancer
Lung
Non-CME Credit Course
Updates in Treatment of Early Stage and Locally Advanced NSCLC
Lung
Non-CME Credit Course
2023 CCC | Advances in Small Cell Lung Cancer and Mesothelioma/Thymic Malignancies
Lung
Non-CME Credit Course
Updates in Targeted Therapy for NSCLC
Lung
Non-CME Credit Course
Updates in Immunotherapy for Lung Cancer
Lung
Non-CME Credit Course
Novel Treatment for Unresectable Stage III NSCLC
Lung
Non-CME Credit Course
Small Cell Lung Cancer: 1L and Beyond
Lung
Non-CME Credit Course
Novel Advances in RT for Oligometastatic Disease
Lung
Non-CME Credit Course
Neoadjuvant and Adjuvant Immunotherapy in Early Stage Lung Cancer
Lung
Non-CME Credit Course
2022 NOSCM | Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?
Lung
Non-CME Credit Course
ADC in NSCLC: TROP2 and HER3 in NSCLC
Lung
Non-CME Credit Course
ADC in NSCLC: CEACAM5 and Teliso-V
Lung
Non-CME Credit Course
Local Advanced NSCLC Neoadjuvant/ Adjuvant Update
Lung
Non-CME Credit Course
2022 MLS New Orleans | Targeted Therapy in Lung Cancer
Lung
Non-CME Credit Course
Immunotherapy in Lung Cancer
Lung
Non-CME Credit Course
2023 MLS Arlington | Management of EGFR/ALK resistance
Lung
Non-CME Credit Course
Favoring The Adjuvant Concept
Lung
Non-CME Credit Course
SCLC Case
Lung
Non-CME Credit Course
Locally Advanced NSCLC (Neoadjuvant/Adjuvant Therapies)
Lung
Non-CME Credit Course
2022 UCT | Novel Mechanisms of Resistance Identified for Tyrosine Kinakse Inhibitors against ALk and Ros1 Tumors in NSCLC
Lung
Non-CME Credit Course
2022 UCT | Advances in Targeted Therapy in Lung Cancer
Lung
Non-CME Credit Course
2022 MLS New Orleans | Mechanism of Resistance to EGFR-ALK & Other Relevant Pathways
Lung
Non-CME Credit Course
2022 MLS New Orleans | Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease
Lung
Non-CME Credit Course
Advances in Small Cell Lung Cancer and Mesothelioma
Lung
Non-CME Credit Course
2022 NOSCM | RET, MET & NTRK Mutations in NSCLC
Lung
Non-CME Credit Course
2022 NOSCM | ALK, ROS1 & BRAF Mutations in NSCLC
Lung
Non-CME Credit Course
2022 NOSCM | EGFR, K-RAS and ERBB2 Mutations in NSCLC
Lung
Non-CME Credit Course
2022 NOSCM | Novel Treatment Strategies for Stage III NSCLC Beyond PACIFIC
Lung
Non-CME Credit Course
2021 NOSCM | Adjuvant and Neoadjuvant Novel Concepts and Strategies in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | Small Cell Lung Cancer: After Immunochemotherapy, What’s Next?
Lung
Non-CME Credit Course
2022 NOSCM | Novel Platforms for Lung Cancer Screening Using Liquid Biopsy
Lung
Non-CME Credit Course
2022 MLS Nashville | Immunotherapy in Advanced/ Metastatic NSCLC
Lung
Non-CME Credit Course
2022 MLS Nashville | Lung Adenocarcinoma Updates
Lung
Non-CME Credit Course
2022 MCM | Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer
Lung
Non-CME Credit Course
Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches
Lung
Non-CME Credit Course
2022 MCM | How to Choose Front Line Therapy for Metastatic Non-Driver Mutation NSCLC
Lung
Non-CME Credit Course
2022 MCM | Lung Cancer Neoadjuvant and Adjuvant Immunotherapy
Lung
Non-CME Credit Course
2022 MCM | Uncommon Mutations/Fusions: EGFRex20ins, RET, MET, Her2, NRG1
Lung
Non-CME Credit Course
2022 MCM | Dealing with EGFRex19del & L858R, ALK, and KRASg12c Genetic Aberrations
Lung
Non-CME Credit Course
2022 MCM | Toxicity Management of Novel Agents in Lung Cancer (RET, MET & KRAS G-12)
Lung
Non-CME Credit Course
Adjuvant and Neo-adjuvant Therapy for Lung Cancer
Lung
Non-CME Credit Course
NTRK and Antibody Drug Conjugates in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | RET, MET & B-RAF mutations in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | ERBB2 and NGR1 Pathways in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | ALK, ROS1 & NTRK Mutations in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | EGFR and K-RAS Mutations in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | Lung Cancer Clinical Scenarios: How Liquid Biopsy Technology Is Delivering Personalized Therapy in NSCLC
Lung
Non-CME Credit Course
2021 NOSCM | State of the Art Radiation in NSCLC
Lung
Non-CME Credit Course
2021 UCT | Novel Mechanisms of Resistance Identified for Diverse TKIs in NSCLC
Lung
Non-CME Credit Course
Lung Cancer Session
Lung
Non-CME Credit Course
Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1
Lung
Non-CME Credit Course
2021 MLS New Orleans | Lung Targeted Therapies in NSCLC: RET, MET and EGFR/HER-2 exon 20
Lung
Non-CME Credit Course
2021 MLS New Orleans | Immunotherapy in Lung
Lung
Non-CME Credit Course
Small cell and Squamous Cell Lung Cancer
Lung
Non-CME Credit Course
2020 Best of WCLC San Francisco | Session IV - Small Cell, Mesothelioma and Thymoma
Lung
Non-CME Credit Course
2020 Best of WCLC San Francisco | Session III - Systemic Treatment for Advanced Stage Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
2020 Best of WCLC San Francisco | Session II - Locally Advanced Non-Small Cell Lung CancerPathology and Biology
Lung
Non-CME Credit Course
2020 Best of WCLC San Francisco | Session I - Screening Prevention Early-Stage Lung Cancer
Lung
Non-CME Credit Course
2021 CCC | Keynote Lecture – The Future of Targeted Therapy in Lung Cancer
Lung
Non-CME Credit Course
2025 WCS | Novel Treatments in NSCLC: Antibody Drug Conjugates (ADC), Bi-Specifics and Vaccines
Lung
Non-CME Credit Course
2021 CCC | How I treat Stage III NSCLC
Lung
Non-CME Credit Course
Lung Cancer
Lung
Non-CME Credit Course
Targeted Therapy in Non-Squamous NSCLC: Where Are We and What Is Coming Up?
Lung
Non-CME Credit Course
Small Cell Lung Cancer - 2 New IO Regimens as Standard of Care
Lung
Non-CME Credit Course
Current State of Lung Cancer Screening
Lung
Non-CME Credit Course
Locally Advanced Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
Small Cell Lung Cancer: Novel Approaches 2019
Lung
Non-CME Credit Course
Squamous Cell Carcinoma of the Lung: Finally Some Progress
Lung
Non-CME Credit Course
RET- MET- and NTRK in Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
Small Cell and Neuroendocrine Carcinoma of The Lung
Lung
Non-CME Credit Course
ALK Mutant NSCLC
Lung
Non-CME Credit Course
Neuroendocrine Tumors of the Lung - A Spectrum of Clinical Challenges
Lung
Non-CME Credit Course
New Developments in Lung Cancer Therapeutics
Lung
Non-CME Credit Course
Small Cell Lung Cancer Novel Approaches
Lung
Non-CME Credit Course
Targeted Therapy for NSCLC
Lung
Non-CME Credit Course
Lung Cancer Case
Lung
Non-CME Credit Course
ALK-Altered Non-Squamous NSCLC Options and Sequence
Lung
Non-CME Credit Course
Roundtable Discussion
Lung
Non-CME Credit Course
Update on the Treatment of Small Cell Lung Cancer and Neuroendocrine Lung Cancers
Lung
Non-CME Credit Course
Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications
Lung
Non-CME Credit Course
How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations
Lung
Non-CME Credit Course
Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
Toxicity Management of Novel Agents in Lung Cancer
Lung
Non-CME Credit Course
Squamous NSCLC and Small Cell Lung Cancer Update
Lung
Non-CME Credit Course
2022 WCS | New Developments for Locally Advanced Lung Cancer
Lung
Non-CME Credit Course
New Therapies for Squamous Cell and Small Cell Lung Carcinomas
Lung
Non-CME Credit Course
Addressing RET, MET, and EGFR/HER-2 Exon 20 insertion
Lung
Non-CME Credit Course
Non-Small Cell Lung Cancer: EGFR, ALK, & K-Ras Pathways
Lung
Non-CME Credit Course
Neo-Adjuvant and Adjuvant Immuntherapy for Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
The Future of Targeted Therapy in Lung Cancer
Lung
Non-CME Credit Course
Small cell and Squamous Cell Lung Cancer Update
Lung
Non-CME Credit Course
Predictive and Prognostic: Value of TMB, MSI and PD-L1 in Liquid and Solid Tumor Specimens.
Lung
Non-CME Credit Course
Liquid Biopsies in Lung Cancer
Lung
Non-CME Credit Course
How to Choose Front Line Therapy for Metastatic NSCLC
Lung
Non-CME Credit Course
EGFR/ALK and ROS-1 Lung Cancer Management
Lung
Non-CME Credit Course
Front Line Metastatic NSCLC
Lung
Non-CME Credit Course
SCLC & Squamous NSCLC - New Standards
Lung
Non-CME Credit Course
NTRK, Exon 20 insertions, and Potential Novel Pathways in NSCLC
Lung
Non-CME Credit Course
RET, MET, and BRAF Mutant Lung Cancer Tumors
Lung
Non-CME Credit Course
EGFR & ALK Inhibitors for Mutated Lung Cancer Tumors
Lung
Non-CME Credit Course
Squamous Cell Carcinoma
Lung
Non-CME Credit Course
RET, MET, NTRK
Lung
Non-CME Credit Course
ALK Mutant NSCLC: What’s New and Do We Have a Sequencing?
Lung
Non-CME Credit Course
Advances in Small Cell Lung Cancer
Lung
Non-CME Credit Course
How I Treat Stage IV Lung Adenocarcinoma without a Driver Mutation and Negative PD-L1 expression
Lung
Non-CME Credit Course
Managing Toxicities from TKI EGFR and ALK Inhibitors
Lung
Non-CME Credit Course
NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer
Lung
Non-CME Credit Course
Lung Cancer Immunotherapy
Lung
Non-CME Credit Course
Small Cell Lung Cancer: Novel Approaches 2019
Lung
Non-CME Credit Course
Updates in Targeted Therapies for NSCLC
Lung
Non-CME Credit Course
The Role of Stereotactic Body Radiation Therapy (SBRT) in Lung Cancer
Lung
Non-CME Credit Course
Neoadjuvant Treatment in Thoracic Surgery
Lung
Non-CME Credit Course
Uncommon Oncogenic Drivers in NSCLC
Lung
Non-CME Credit Course
Targeted and Immune Therapies in Lung Cancer
Lung
Non-CME Credit Course
Current Issues in Checkpoint Immunotherapy for NSCLC
Lung
Non-CME Credit Course
Evolving Treatment Options in EGFR-mutant NSCLC
Lung
Non-CME Credit Course
Oncogene-Driven NSCLC
Lung
Non-CME Credit Course
Small Cell and Neuroendocrine Carcinoma of the Lung
Lung
Non-CME Credit Course
RET, MET, & NTRK in Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
New Landscape of Mutant EGFR & ALK Lung Cancer Patients
Lung
Non-CME Credit Course
Other Driver Mutations in Lung Cancer - RET,ERBB2, MET, NTRK
Lung
Non-CME Credit Course
Immunotherapy in Neoadjuvant - Adjuvant &Stage III NSCLC
Lung
Non-CME Credit Course
Management of EGFR-mutant NSCLC
Lung
Non-CME Credit Course
Liquid Biopsy in the Management of Lung Cancer
Lung
Non-CME Credit Course
Updates in Immunotherapy for Lung Cancer: Integration of Predictive Biomarkers
Lung
Non-CME Credit Course
2025 WCS | First-Line Targeted Therapies in NSCLC: What’s New?
Lung
Non-CME Credit Course
2025 WCS | Immunotherapy for NSCLC: First Line and What Is After Progression?
Lung
Non-CME Credit Course
2025 WCS | Neoadjuvant-Adjuvant-Perioperative Immunotherapy in NSCLC
Lung
Non-CME Credit Course
2025 WCS | Limited- and Extensive-Disease Small Cell Lung Cancer (SCLC): New Standard of Care and Novel Advances
Lung
Non-CME Credit Course
Perioperative Immunotherapy in NSCLC
Lung
Non-CME Credit Course
Antibody Drug Conjugates in Lung Cancer
Lung
Non-CME Credit Course
New Developments in Small Cell Lung Cancer
Lung
Non-CME Credit Course
2022 Best of WCLC | Small Cell Lung Cancer
Lung
Non-CME Credit Course
New Therapeutic Directions in Lung Cancer
Lung
Non-CME Credit Course
Updates in Locally Advanced Unresectable (Stage III) NSCLC
Lung
Non-CME Credit Course
Advances in Limited and Extensive Stage Small Cell Lung Cancer
Lung
Non-CME Credit Course
Updates in Immunotherapy for Metastatic Lung Cancer
Lung
Non-CME Credit Course
Perioperative Therapy and Predictive Biomarkers in Early Stage Non Small Cell Lung Cancer
Lung
Non-CME Credit Course
Mesothelioma and Thymoma – Limited and Advanced Stage
Lung
Non-CME Credit Course
Other Immunotherapy Targets & Agents- Advanced NSCLC
Lung
Non-CME Credit Course
PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC
Lung
Non-CME Credit Course
2022 Best of WCLC | EGFR Mutated Lung Cancer - Advanced Stage
Lung
Non-CME Credit Course
ALK, ROS1, and BRAF Positive Lung Cancer
Lung
Non-CME Credit Course
2022 Best of WCLC | Tumor Biology, Pathology, Novel Diagnostics
Lung
Non-CME Credit Course
2023 Best of WCLC San Francisco | Palliative Care Approaches in Lung Cancer
Lung
Non-CME Credit Course
Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy
Lung
Non-CME Credit Course
Stage III NSCLC – Surgical/Combined Modality
Lung
Non-CME Credit Course
Locally Advanced NSCLC- Radiation Therapy
Lung
Non-CME Credit Course
2022 Best of WCLC | Radiation in Early-Stage NSCLC
Lung
Non-CME Credit Course
2022 Best of WCLC | Adjuvant/Neo-adjuvant Systemic Therapy
Lung
Non-CME Credit Course
Surgery for Early-Stage NSCLC
Lung
Non-CME Credit Course
Pulmonary – From Diagnostics to Therapeutics
Lung
Non-CME Credit Course
Lung Cancer Screening / Tobacco Control
Lung
Non-CME Credit Course
2024 Small Cell Lung Cancer
Lung
Non-CME Credit Course
2024 Metastatic Non-Small Cell Lung Cancer
Lung
Non-CME Credit Course
BRAF and NTRK Inhibitors in NSCLC
Lung
Non-CME Credit Course
The Future of SCLC Treatment: Potential Agents and Where Are We Going?
Lung
Non-CME Credit Course
Treatment for SCLC in 2024: Where Are We At?
Lung
Non-CME Credit Course
Assessing Resectability in Stage III NSCLC
Lung
Non-CME Credit Course
Update Progress in Targeted Therapies for Early-Stage NSCLC
Lung
Non-CME Credit Course
Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms
Lung
Non-CME Credit Course
Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?
Lung
Non-CME Credit Course
Contact Us
